公开(公告)号：US20230233671A1

公开(公告)日：2023-07-27

申请号：US18045967

申请日：2022-10-12

Applicant: Pfizer Inc.

Inventor： Eric Matthew Bennett ,  Fernando Martin Diaz ,  Philip Ralph Dormitzer ,  Kathrin Ute Jansen ,  Raquel Munoz-Moreno ,  Alicia Solorzano Quijano

IPC: A61K39/25 ,  A61K47/69 ,  A61K47/10 ,  A61K47/28 ,  A61P37/04

CPC classification number: A61K39/25 ,  A61K47/6929 ,  A61K47/10 ,  A61K47/28 ,  A61P37/04

Abstract: The present disclosure relates to RNA molecules encoding a varicella zoster virus (VZV). The present disclosure further relates to compositions comprising the RNA molecules formulated in a lipid nanoparticle (RNA-LNP). The present disclosure further relates to the use of the RNA molecules, RNA-LNPs and compositions for the treatment or prevention of herpes zoster or shingles.

公开(公告)号：US20190125861A1

公开(公告)日：2019-05-02

申请号：US16242799

申请日：2019-01-08

Applicant: Pfizer Inc.

Inventor： Ye Che ,  Philip Ralph Dormitzer ,  Alexey Vyacheslavovich Gribenko ,  Luke David Handke ,  Avvari Krishna Prasad ,  Xiayang Qiu ,  Mark Edward Ruppen ,  Xi Song ,  Kena Anne Swanson ,  Srinivas Kodali ,  Xin Xu ,  KariAnn Sweeney Efferen ,  Ping Cai ,  Kristin Rachael Tompkins ,  Lorna del Pilar Nunez

IPC: A61K39/155 ,  C07K14/005 ,  A61K39/12 ,  C12N7/00

Abstract: The present disclosure relates to RSV F protein mutants, nucleic acids or vectors encoding a RSV F protein mutant, compositions comprising a RSV F protein mutant or nucleic acid, and uses of the RSV F protein mutants, nucleic acids or vectors, and compositions.

公开(公告)号：US20230218738A1

公开(公告)日：2023-07-13

申请号：US18192352

申请日：2023-03-29

Applicant: Pfizer Inc.

Inventor： Ye Che ,  Philip Ralph Dormitzer ,  Alexey Vyacheslavovich Gribenko ,  Luke David Handke ,  Avvari Krishna Prasad ,  Xiayang Qiu ,  Mark Edward Ruppen ,  Xi Song ,  Kena Anne Swanson ,  Srinivas Kodali ,  Xin Xu ,  KariAnn Sweeney Efferen ,  Ping Cai ,  Kristin Rachael Tompkins ,  Lorna del Pilar Nunez

IPC: C07K14/005 ,  A61K39/155

CPC classification number: C07K14/005 ,  A61K39/155 ,  A61K2039/575

Abstract: The present disclosure relates to RSV F protein mutants, nucleic acids or vectors encoding a RSV F protein mutant, compositions comprising a RSV F protein mutant or nucleic acid, and uses of the RSV F protein mutants, nucleic acids or vectors, and compositions.

公开(公告)号：US10821171B2

公开(公告)日：2020-11-03

申请号：US16242799

申请日：2019-01-08

Applicant: Pfizer Inc.

Inventor： Ye Che ,  Philip Ralph Dormitzer ,  Alexey Vyacheslavovich Gribenko ,  Luke David Handke ,  Avvari Krishna Prasad ,  Xiayang Qiu ,  Mark Edward Ruppen ,  Xi Song ,  Kena Anne Swanson ,  Srinivas Kodali ,  Xin Xu ,  KariAnn Sweeney Efferen ,  Ping Cai ,  Kristin Rachael Tompkins ,  Lorna del Pilar Nunez

IPC: A61K39/155 ,  C07K14/135 ,  A61K39/12 ,  C07K14/005 ,  C12N7/00 ,  A61K39/00

Abstract: The present disclosure relates to RSV F protein mutants, nucleic acids or vectors encoding a RSV F protein mutant, compositions comprising a RSV F protein mutant or nucleic acid, and uses of the RSV F protein mutants, nucleic acids or vectors, and compositions.

公开(公告)号：US20220362372A1

公开(公告)日：2022-11-17

申请号：US17733566

申请日：2022-04-29

Applicant: PFIZER INC.

Inventor： Philip Ralph Dormitzer ,  Advait Vijay Badkar ,  Christina Van Geen Hoven ,  Kathrin Ute Jansen ,  Pirada Suphaphiphat Allen ,  Ramin Darvari ,  Mark Duda

IPC: A61K39/145 ,  A61P31/16

Abstract: The invention relates to compositions and methods for the preparation, manufacture and therapeutic use ribonucleic acid vaccines comprising polynucleotide molecules encoding one or more influenza antigens, such as hemagglutinin antigens.

公开(公告)号：US09950058B2

公开(公告)日：2018-04-24

申请号：US15385611

申请日：2016-12-20

Applicant: Pfizer Inc.

Inventor： Ye Che ,  Philip Ralph Dormitzer ,  Alexey Vyacheslavovich Gribenko ,  Luke David Handke ,  Avvari Krishna Prasad ,  Xiayang Qiu ,  Mark Edward Ruppen ,  Xi Song ,  Kena Anne Swanson ,  Srinivas Kodali ,  Xin Xu ,  KariAnn Sweeney Efferen ,  Ping Cai ,  Kristin Rachael Tompkins ,  Lorna del Pilar Nunez

IPC: A61K39/155 ,  C07K14/135 ,  C12N15/01 ,  C07K14/005 ,  C12N7/00 ,  A61K39/12 ,  A61K39/00

CPC classification number: A61K39/155 ,  A61K39/12 ,  A61K2039/575 ,  C07K14/005 ,  C07K2319/02 ,  C07K2319/21 ,  C07K2319/22 ,  C07K2319/40 ,  C07K2319/70 ,  C07K2319/735 ,  C12N7/00 ,  C12N2760/18522 ,  C12N2760/18534 ,  C12N2760/18571

Abstract: The present disclosure relates to RSV F protein mutants, nucleic acids or vectors encoding a RSV F protein mutant, compositions comprising a RSV F protein mutant or nucleic acid, and uses of the RSV F protein mutants, nucleic acids or vectors, and compositions.

公开(公告)号：US20240299587A1

公开(公告)日：2024-09-12

申请号：US18277425

申请日：2022-02-21

Applicant: Pfizer Inc.

Inventor： Xiaoyuan Sherry Chi ,  Philip Ralph Dormitzer ,  Weifeng Liu ,  Yuhang Liu

IPC: A61K49/00 ,  A61K38/16 ,  A61P31/22

CPC classification number: A61K49/0004 ,  A61K38/162 ,  A61P31/22

Abstract: The present invention relates to a method for identifying a candidate therapeutic for a disease caused by infection with a human cytomegalovirus (HCMV) having a glycoprotein B (gB) polypeptide, comprising contacting the HCMV gB polypeptide comprising a druggable region with a compound, wherein binding of said compound indicates a candidate therapeutic. The present invention also relates to candidate therapeutics comprising modulators and inhibitors of HCMV activity and pharmaceutical compositions comprising said modulators and inhibitors and methods of use thereof.

公开(公告)号：US20240100153A1

公开(公告)日：2024-03-28

申请号：US18506578

申请日：2023-11-10

Applicant: Pfizer Inc.

Inventor： Yuhang Liu ,  Ye Che ,  Xiaoyuan Sherry Chi ,  Philip Ralph Dormitzer ,  Jennifer Anne Nicki ,  Xiaojie Yao

IPC: A61K39/245 ,  C07K14/045 ,  C12N7/00

CPC classification number: A61K39/245 ,  C07K14/045 ,  C12N7/00 ,  C12N2710/16134

Abstract: The present invention relates to polypeptides and cytomegalovirus (CMV) antigens that include at least two introduced amino acid mutations relative to the amino acid sequence of the wild-type HCMV glycoprotein B (gB). In some embodiments, the polypeptide is stabilized in a conformation alternative to the gB postfusion conformation. Also disclosed are compositions including the polypeptides and uses thereof.

公开(公告)号：US20220088184A1

公开(公告)日：2022-03-24

申请号：US17350008

申请日：2021-06-17

Applicant: Pfizer Inc.

Inventor： Yuhang Liu ,  Ye Che ,  Xiaoyuan Sherry Chi ,  Philip Ralph Dormitzer ,  Jennifer Anne Nicki ,  Xiaojie Yao

IPC: A61K39/245 ,  C07K14/045 ,  C12N7/00

Abstract: The present invention relates to polypeptides and cytomegalovirus (CMV) antigens that include at least two introduced amino acid mutations relative to the amino acid sequence of the wild-type HCMV glycoprotein B (gB). In some embodiments, the polypeptide is stabilized in a conformation alternative to the gB postfusion conformation. Also disclosed are compositions including the polypeptides and uses thereof.

公开(公告)号：US20210023200A1

公开(公告)日：2021-01-28

申请号：US17060944

申请日：2020-10-01

Applicant: Pfizer Inc.

Inventor： Ye Che ,  Philip Ralph Dormitzer ,  Alexey Vyacheslavovich Gribenko ,  Luke David Handke ,  Avvari Krishna Prasad ,  Xiayang Qiu ,  Mark Edward Ruppen ,  Xi Song ,  Kena Anne Swanson ,  Srinivas Kodali ,  Xin Xu ,  KariAnn Sweeney Efferen ,  Ping Cai ,  Kristin Rachael Tompkins ,  Lorna del Pilar Nunez

IPC: A61K39/155 ,  A61K39/12 ,  C07K14/005 ,  C12N7/00

Abstract: The present disclosure relates to RSV F protein mutants, nucleic acids or vectors encoding a RSV F protein mutant, compositions comprising a RSV F protein mutant or nucleic acid, and uses of the RSV F protein mutants, nucleic acids or vectors, and compositions.